In a powerful show of community health advocacy, Guardant Health and The Dolphins Cancer Challenge (DCC) joined forces on Saturday to host a groundbreaking colorectal cancer (CRC) screening event in the Dolphin Fan Zone at Hard Rock Stadium. The initiative timing ahead of the Dolphin Jaguars preseason games, highlighting the importance of early detection and providing access to participants in ShieldTM, the first FDA-approved blood test for CRC screening.
Shield tests developed by Guardant Health allow eligible individuals to screen for colorectal cancer in a simple blood draw.
“The CRC is the second leading cause of cancer-related deaths in the United States, but has a 91% five-year survival rate when caught up in the early stages, so screening and early detection is important.” “By bringing shield testing directly to the Miami community here at Hard Rock Stadium, we are taking a positive step towards breaking screening barriers through non-invasive blood tests and reaching people who may not otherwise be tested.”
Among those screened was the legendary Nat Moore of the Miami Dolphins. He shared his personal commitment to active healthcare and encouraged others to follow suit.
“Careing on my health has always been a priority, and as I get older I have come to realize how important regular screening is, especially for cancers like colon cancer, so I didn’t hesitate to get screened myself,” Moore said. “I am proud to be in the South Florida community with so many people in the South Florida community that are stepping up to control their health through innovative screening methods such as shield testing.”
This event is part of a larger mission by Guardant Health and DCC, closing the CRC screening gap and supporting cancer research. DCC continues to be the driving force behind the fight against cancer in South Florida.
Adults over the age of 45 are encouraged to talk to their healthcare provider about CRC screening options or visit https://shieldcancerscreen.com.
About Guardant Health
Guardant Health is a leading precision tumor company focused on protecting health and giving everyone more time from cancer. Founded in 2012, Guardant transforms patient care and accelerates new cancer therapies by providing important insights into why disease is promoted through advanced blood and histological examinations, real data, and AI analysis. Gardant testing can help improve outcomes across all stages of care, including screening for early cancer detection, monitoring early cancer recurrence, and treatment choices for patients with advanced cancer. For more information, visit guardanthealth.com and follow our LinkedIn, X (Twitter) and Facebook companies.
